G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022 – By Type (Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Others), By Product: Tablet, Capsule, Others) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : February 2022 | SKU CODE : 7739 | Delivery Time: 2-3 business days | Format :


The G-CSF (Granulocyte Colony Stimulating Factors) market consists of sales of G-CSF drugs and relates services. Granulocyte colony-stimulating factor is a drug used to treat neutropenia, a disorder in which there is a lower-than-average number of white blood cells, caused by certain forms of chemotherapy.

The main types of G-CSF are lenograstim (granocyte), filgrastim (neupogen, zarzio, nivestim, accofil), long acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco) and lipegfilgrastim (lonquex). Lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to or identical to a naturally occurring human granulocyte colony-stimulating factor. The different products include tablet, capsule, others and is used in oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders, others.

The global G-CSF (granulocyte colony stimulating factors) market size is expected to grow from $7.37 billion in 2021 to $7.99 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The G-CSF market is expected to reach $9.48 billion in 2026 at a CAGR of 4.4%.

The increasing prevalence of cancer is a key factor driving the growth of the Granulocyte Colony Stimulating Factors market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and ageing. About 70% of deaths from cancer occur in low- and middle-income countries. G-CSF is a class of growth factor which produces white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infection after certain forms of treatment for cancer. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF market.

The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is another key factor driving the growth of the granulocyte-colony stimulating factor market. The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor is expected to drive the growth of the granulocyte-colony stimulating factor market.

The high cost is a key factor limiting the growth of the G-CSF market. Improved chemotherapy administration is responsible for the rise in instant medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57% increase in total Medicare costs during the study period, despite a fall in medical costs for neutropenia. Around 42% of the increase can be attributed to the rise in the costs of chemotherapy. Each shot of PPG-CSF costs more than $250. Therefore, the high cost is expected to hinder the growth of the Granulocyte Colony Stimulating Factors market.

In June 2019, Pfizer Inc., a US-based pharmaceutical corporation, acquired Array BioPharma Inc. for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. This acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory, particularly in the long term. Array BioPharma Inc is a US-based company, is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Major players in the G-CSF (Granulocyte Colony Stimulating Factors) market are BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, Stada Arzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy's Laboratories and Celltrion Inc.

The regions covered in the Granulocyte Colony Stimulating Factors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the G-CSF market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global G-CSF (granulocyte colony stimulating factors) market is segmented -

1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)

2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders, Others

3) By Product: Tablet, Capsule, Others

    Table Of Contents

    1. Executive Summary

    2. G-CSF (Granulocyte Colony Stimutating Factors) Market Characteristics

    3. G-CSF (Granulocyte Colony Stimutating Factors) Market Trends And Strategies

    4. Impact Of COVID-19 On G-CSF (Granulocyte Colony Stimutating Factors)

    5. G-CSF (Granulocyte Colony Stimutating Factors) Market Size And Growth

    5.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. G-CSF (Granulocyte Colony Stimutating Factors) Market Segmentation

    6.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Lenograstim (Granocyte)

    Filgrastim (Neupogen, Zarzio, Nivestim, Accofil)

    Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco)

    Lipegfilgrastim (Lonquex)

    6.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oncological Diseases

    Blood Disorders

    Growth Hormone Deficiencies

    Chronic and Autoimmune Disorders

    Others

    6.3. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Tablet

    Capsule

    Others

    7. G-CSF (Granulocyte Colony Stimutating Factors) Market Regional And Country Analysis

    7.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market

    8.1. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China G-CSF (Granulocyte Colony Stimutating Factors) Market

    9.1. China G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    9.2. China G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India G-CSF (Granulocyte Colony Stimutating Factors) Market

    10.1. India G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market

    11.1. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market

    12.1. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market

    13.1. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market

    14.1. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market

    15.1. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    15.2. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK G-CSF (Granulocyte Colony Stimutating Factors) Market

    16.1. UK G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market

    17.1. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France G-CSF (Granulocyte Colony Stimutating Factors) Market

    18.4. France G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market

    19.1. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    19.2. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market

    20.1. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America G-CSF (Granulocyte Colony Stimutating Factors) Market

    21.1. North America G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    21.2. North America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA G-CSF (Granulocyte Colony Stimutating Factors) Market

    22.1. USA G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    22.2. USA G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America G-CSF (Granulocyte Colony Stimutating Factors) Market

    23.1. South America G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    23.2. South America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market

    24.1. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market

    25.1. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    25.2. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market

    26.1. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    26.2. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. G-CSF (Granulocyte Colony Stimutating Factors) Market Competitive Landscape And Company Profiles

    27.1. G-CSF (Granulocyte Colony Stimutating Factors) Market Competitive Landscape

    27.2. G-CSF (Granulocyte Colony Stimutating Factors) Market Company Profiles

    27.2.1. BioCad

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Teva Pharmaceuticals

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Pfizer

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Intas Pharmaceuticals

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Novartis AG

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. G-CSF (Granulocyte Colony Stimutating Factors) Pipeline Analysis

    29. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimutating Factors) Market

    30. G-CSF (Granulocyte Colony Stimutating Factors) Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: BioCad Financial Performance
  • Table 47: Teva Pharmaceuticals Financial Performance
  • Table 48: Pfizer Financial Performance
  • Table 49: Intas Pharmaceuticals Financial Performance
  • Table 50: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: BioCad Financial Performance
  • Figure 47: Teva Pharmaceuticals Financial Performance
  • Figure 48: Pfizer Financial Performance
  • Figure 49: Intas Pharmaceuticals Financial Performance
  • Figure 50: Novartis AG Financial Performance
Global Contract Research And Manufacturing Services (CRAMS) Market Size, Forecasts, And Opportunities – Includes CRAMS Market Overview
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Oncology Molecular Diagnostics Global Market Report 2022 – By Product (Instruments, Reagents), By Technology (Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips & Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA)), By End User (Hospitals, Diagnostic Centers, Academic & Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Ambulatory IV Infusion Pumps Global Market Report 2022 – By Type (Disposable Infusion Pumps, Chemotherapy Infusion Pump), By End-User (Hospitals, Home Healthcare, Other End Users), By Application (Chemotherapy/Oncology, Diabetes, Gastroenterology, Analgesia/Pain Management, Pediatrics/Neonatology, Hematology, Other Applications) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Clinical Oncology Next Generation Sequencing Global Market Report 2022 – By Technology (Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing), By Application (Screening, Companion Diagnostics, Other Diagnostics), By End-User (Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Drugs For Hormonal Replacement Therapy Global Market Report 2022 – By Therapy Type (Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause), By Route of Administration (Oral, Parental) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Oncology Drugs Global Market Report 2022 – By Type (Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biosimilar Growth Hormones Global Market Report 2022 – By Route Of Administration (Intravenous, Subcutaneous, Intramuscular, Oral), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/Epharmacy, Speciality Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Antisense & RNAi Therapeutics Global Market Report 2022 – By Technology (RNA Interference, Antisense RNA), By Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery), By Indication (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biosimilar Monoclonal Antibodies Global Market Report 2022 – By Type (Synthetic Chemicals, Biopharmaceuticals), By Application (Chronic & Autoimmune Diseases, Oncology), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab) – Market Size, Trends, And Global Forecast 2022-2026
View Report